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to sPTV. The mean V20 values was 7.8% for dynamic tracking 
SBRT (tV20) and 8.1% for static SBRT (sV20), corresponding to 
an average reduction of 11.2 ± 5.9% (p = 0.016) in the tV20 
compared to sV20. 
Conclusions: This study demonstrates that lung SBRT with 
DTT reduces treatment volumes and dose to normal lung 
tissue. Further clinical outcome data are required to validate 
these findings.  
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Purpose/Objective: Radiotoxicity during radiotherapy of lung 
cancer may be misdiagnosed as pneumonia or respiratory 
tract infections which prevents the patients from getting 
optimal treatment. We evaluated changes of three 
inflammation-associated cytokines in patients undergoing 
radiotherapy for non-small cell lung cancer (NSCLC) to 
establish changes of their levels and evaluate which of the 
markers: Interleukin 6 (IL-6), Tumour necrosis factor-alpha 
(TNF-a) or Lipopolysaccharide-binding protein (LBP) are 
specifically affected by radiation dose received by the 
pulmonary and mediastinal structures rather than infection. 
Materials and Methods: In this pilot phase of the project we 
evaluated 29 patients treated for NSCLC by means of 
2.0Gy/daily schemes with total target doses in the range of 
60-74Gy. Cytokines were measured before start of treatment, 
on the day of reaching the total dose of 20Gy and at 40Gy. An 
age-matched control group of 8 individuals was used to 
establish differences in baseline cytokine levels. Data from 
the 40Gy time-point were correlated with histogram 
parameters of the radiotherapy protocol. ELISA kits were 
used for cytokine quantification (IL-6 and TNF-a by R&D, USA 
and LBP by Abnova, Taiwan). Arithmetical means were used 
for LBP, while geometrical means were used to represent 
results of IL-6 and TNF-a due to non-normal distribution of 
values. 
Results: Average age of the group was 64.61+/-6.57 years, 
majority of patients were male (18 vs 11). The group with 
NSCLC showed higher than controls baseline levels of IL-6 
(5.11+/-2.52 vs 2.18+/-2.19; p=0.02) and marginally higher 
TNF-a (17.94+/-1.16 vs 16.30+/-1.17; p=0.12). No such 
differences were seen in LPB levels (35.86+/-8.45 vs 32.69+/-
9.38; p=0.36). Levels of all three cytokines remained 
unchanged during treatment: IL-6 5.11+/-2.52; 4.59+/-1.86 
and 6.15+/-4.00 (p=0.25); TNF-a 17.94+/-1.16; 17.56+/-1.18 
and 19.88+/-1.74 (p=0.47); LBP 35.87+/-8.45; 35.72+/-7.58 
and 35.82+/-7.06 (p=0.36). However, at the 40Gy timepoint, 
positive, significant correlations were noted for LBP and lung 
volume subjected to 5Gy (r=0.52, p=0.01), 20Gy (r=0.41, 
p=0.049) and mean radiation dose planned for lung tissue 
(r=0.49, p=0.02, Figure 1). Neither IL-6 nor TNF-a showed 
such associations, hinting at the specificity of LBP reaction to 
lung irradiation. 
 
 
Conclusions: LBP levels correlate with radiation exposure of 
pulmonary tissue regardless of infectious causes and can be 
used for further studies on radiotoxicity in NSCLC patients. 
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Purpose/Objective: Patients with lung cancer undergoing 
radiotherapy (RT) are at risk of lung-related toxicity such as 
radiation pneumonitis (RP). It has been reported that RP 
occurs after initiation of radiotherapy for a wide range of 
doses in the normal lung tissue. In addition to RT, the effect 
of targeted therapy such as erlotinib on normal lung needs to 
be considered. Medical imaging may be employed for 
detection of normal tissue effects from RT and erlotinib. This 
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study employs FDG-PET/CT to study the response patterns in 
normal lung and to potentially identify cytotoxic effects. 
Materials and Methods: This project included 22 patients 
with advanced-stage non-small cell lung cancer, participating 
in a phase II trial of combined radiation and erlotinib-
therapy. The patients underwent three PET-CT examinations; 
pre-therapy, mid-therapy, and six weeks after fractionated 
radiotherapy (3Gy x 10). Nine patients received fractionated 
RT only, while 13 patients received erlotinib (150 mg p.o. 
daily) and fractionated RT. For each patient, lung was 
delineated in the planning CT before the initiation of 
treatment. The RT dose matrix was co-registered with the 
PET/CT image series. The FDG-uptake distribution, in terms 
of the standardized uptake value (SUV), was obtained for 
lung from all PET-CT examinations. In order to identify the 
association between SUV and RT dose, SUVmean was calculated 
in dose bins of 0.5 Gy. Linear regression was applied to 
extract trends in the dose-SUV relationship. The effect of 
erlotinib was investigated by separating patients into 
erlotinib receiving and a non-erlotinib receiving groups. 
Results: A positive linear relationship was identified between 
SUV and RT dose in the lung at both mid- and post-therapy, 
considering all patients. A significant increase (15%) in FDG-
uptake at all dose levels was observed from mid- to post-
therapy. Separating patients based on erlotinib treatment, a 
positive correlation between SUV and RT dose was identified 
for both groups at mid-therapy. However, the FDG-uptake 
was significantly higher (16%) in the erlotinib-receiving 
group. At post-therapy, patients receiving erlotinib again had 
a significantly elevated FDG-uptake in lung compared to non-
erlotinib receiving patients, but the association with RT dose 
for erlotinib-receiving patients was absent. 
Conclusions: Normal lung glucose metabolism positively 
correlated with RT dose during the first week of treatment. 
This could indicate RP in the lung. Erlotinib increased the 
FDG uptake in the lung compared to RT only. This study 
indicates that more detailed follow-up of lung toxicity in 
patients undergoing erlotinib therapy is required. Also, 
deeper mechanistic studies into the biological action of RT 
and erlotinib in the healthy lung are warranted. 
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Purpose/Objective: The aim of the study was to evaluate the 
interest of weekly Cone Beam CT (CBCT) to predict the risk 
of local recurrence and survival in case of radio-
chemotherapy (RT-CT) for locally advanced NSCLC (LA-
NSCLC). 
Materials and Methods: Between August 2011 and March 
2014, a series of 21 patients (pts) with a mean age of 67 
years (49-81 years) and presenting a LA-NSCLC (stage IIIA or 
IIIB) were treated by RT-CT. The total dose was 66 Gy at 2.2 
Gy/fraction over 6 weeks delivered by IMRT and IGRT using 
CBCT. Weekly CBCT were used to delineate the primary 
tumor (TV), excluding the mediastinal lymph nodes. The 
response during treatment was quantified by the ratio 
between the primary TV delineated in the weekly CBCT and 
the primary TV delineated in the planning CT. Recurrence 
after treatment was evaluated by 18 Fluoro-deoxy-glucose 
PET and CT scan, performed every 3 months during the first 
two years of follow up. Cox regression model was used to test 
the impact of TV ratio, as continuous values, in the risk of 
local recurrence and death. ROC analysis was used to identify 
TV ratio threshold values. 
Results: The median follow up was 16 months (6-33 months). 
Ten pts (47.6%) presented local failure (LF). The risk of local 
failure at 18 months was 54 % (CI 95%: 30-78%). The OS rate 
at 18 months was 85% (CI 95%: 70-100%). The mean (range) 
TV ratio at week 1, 2, 3, 4, 5 and 6 were: 0.92, (0.5-1.9), 
0.82 (0.3-1.45), 0.75 (0.25-1.42), 0.67 (0.18-1.4), 0.6 (0.15-
1.5) and 0.53 (0.13-0.9) respectively, corresponding to a 
mean tumor regression during treatment of 8% per week. In 
univariate analysis, TV ratios, as continuous values, at the 
fifth and sixth week were predictive of both local failure and 
death (p≤0.04). TV ratio at the fourth week was predictive of 
local failure only (p=0.02). Threshold value of TV ratio 
between 0.7 and 0.8 appears particularly discriminant. 
Conclusions: Monitoring TV in weekly CBCT during RT-CT for 
LA-NSCLC appears useful to predict the risk of recurrence and 
death, identifying pts candidates for treatment 
intensification. A larger series is needed to confirm these 
results and to perform multivariate analysis.  
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Purpose/Objective: The management of intrapulmonary 
recurrence after lung cancer surgery is a challenging 
proposition because of poor lung function. Stereotactic body 
radiotherapy (SBRT) has achieved a good tumor control with 
preserving lung function. The purpose of this study is to 
evaluate the safety and efficacy of SBRT for recurrent lung 
cancer after surgery. 
Materials and Methods: Between July 2008 and September 
2013, 27 patients with intrapulmonary recurrence after lung 
cancer surgery received SBRT at our institution. We 
conducted a retrospective analysis of all these patients (4 
women and 23 men). The median age was 73 years (range, 50 
to 92 years). The median forced expiratory volume in 1 
second before SBRT was 1820ml (range, 920 to 2520ml). The 
prescribed doses were 48Gy in 4 fractions, 60Gy in 10 
fractions, and 50Gy in 10 fractions. Toxicity was graded via 
RTOG/EORTC late radiation morbidity scoring. Overall 
survival (OS) was calculated by the Kaplan-Meier method. 
Results: The median follow up time from SBRT was 2.0 years. 
All patients completed the planned treatment without severe 
acute adverse event. One patient died due to radiation 
pneumonitis after 7 months from SBRT. One patient had 
grade 3 radiation pneumonitis, and one had grade 2. The 
